Overview

Welcome to Stayble Therapeutics AB´s IR pages

Stayble Therapeutics is a clinical stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. STA363 is intended for patients not improving after treatment with analgesics and physiotherapy.

LATEST PRESS RELEASES

20 May 2020 Regulatory

Stayble receives approval from regulatory authorities to start clinical phase 2b study with STA363 in Russia

Stayble announces today, May 20, 2020, that the Russian regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The Company has previ...

01 May 2020 Regulatory

Stayble receives approval from regulatory authorities to start clinical phase 2b study in Spain

Stayble announces today, May 1, 2020, that the Spanish regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The Company has previo...

FINANCIAL CALENDAR

Annual meeting
8June2020
Interim report Q2 2020
17August2020
Interim report Q3 2020
16November2020
Interim report Q4 2020
15February2021